Iqbal Hussain Sells 38,951 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Iqbal Hussain sold 38,951 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the completion of the transaction, the insider directly owned 57,645 shares in the company, valued at approximately $1,449,771.75. This represents a 40.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA opened at $25.00 on Thursday. The company has a market capitalization of $3.36 billion, a P/E ratio of -13.66 and a beta of 1.56. The company’s 50-day moving average is $25.32 and its 200 day moving average is $22.62. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. Centessa Pharmaceuticals PLC Sponsored ADR has a fifty-two week low of $9.60 and a fifty-two week high of $30.58.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). On average, equities research analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several large investors have recently added to or reduced their stakes in CNTA. TD Waterhouse Canada Inc. purchased a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at about $25,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Centessa Pharmaceuticals by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after buying an additional 979 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new position in shares of Centessa Pharmaceuticals in the 2nd quarter worth $218,000. DNB Asset Management AS bought a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter worth $218,000. Finally, Sigma Planning Corp bought a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth $225,000. Institutional investors own 82.01% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on CNTA shares. Guggenheim increased their price objective on Centessa Pharmaceuticals from $28.00 to $43.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Piper Sandler reiterated an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. Truist Financial boosted their price objective on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. Wells Fargo & Company upped their price objective on shares of Centessa Pharmaceuticals from $30.00 to $35.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Finally, Chardan Capital reiterated a “buy” rating and issued a $30.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, January 2nd. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.50.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.